News Release: July 29, 2025
Nodakenin Price Trend in Past Five Years and Factors Impacting Price Movements (2019–2024)
Over the last five years, Nodakenin has seen significant fluctuations in pricing, driven by both demand-side and supply-side factors. The price of Nodakenin, a bioactive compound extracted from Angelica gigas and used predominantly in pharmaceuticals and herbal formulations, has been sensitive to agricultural output, extraction technology, demand from pharmaceutical manufacturers, and global logistics dynamics.
In 2019, Nodakenin prices averaged around $5,200/MT. This was a relatively stable year, with moderate production in South Korea and China, and steady demand across Asia-Pacific. Moving into 2020, disruptions caused by the COVID-19 pandemic led to constrained production and limited transportation capacities. These factors pushed prices up to approximately $5,850/MT by the fourth quarter of 2020.
In 2021, there was a partial recovery in supply chains, and several mid-sized pharmaceutical companies began to experiment with Nodakenin-based formulations. This increased demand slightly while production resumed in key regions. The average Nodakenin price for 2021 was around $6,100/MT, climbing due to both raw material shortages and strong end-use sector demand.
The year 2022 witnessed more aggressive price increases, with Nodakenin touching $6,700/MT by the end of the year. This increase was driven by a combination of higher raw material costs and increased export demand from European markets, particularly in nutraceutical applications. Nodakenin sales volume saw a rise, but the extraction yield per metric ton of Angelica gigas declined due to environmental factors in key growing regions, contributing to cost increases.
In 2023, the Nodakenin price trend continued upwards, with an average price of $7,050/MT. Production saw a boost with new facilities in Vietnam and South Korea coming online, but demand from North American pharmaceutical companies pushed prices further. Additionally, increased regulatory scrutiny in Europe on herbal products made production standards stricter, adding to processing costs.
The first half of 2024 was marked by a marginal price correction. Nodakenin price dropped to an average of $6,600/MT due to improved crop yields and expansion of high-efficiency extraction plants in China. However, by the end of 2024, Nodakenin price news reported a resurgence to $6,950/MT, as demand rebounded with the introduction of new functional supplements in the US and Europe that included Nodakenin as a primary ingredient.
Key factors impacting price movements over this five-year span include climatic changes affecting Angelica gigas cultivation, innovations in extraction technology, global transportation costs, regulatory changes in herbal medicine markets, and patent filings for Nodakenin-based pharmaceutical products.
Nodakenin price trend and production News
Nodakenin Price Trend Quarterly Update in $/MT (2025 Estimated)
Below is the estimated quarterly pricing for Nodakenin in 2025 based on production levels, demand forecasts, and macroeconomic indicators:
- Q1 2025: $7,200/MT
- A strong demand cycle from pharmaceutical buyers in Europe and the US has kept prices high. Raw material shortages from delayed harvesting in South Korea also played a role.
- Q2 2025: $7,050/MT
Slight improvement in crop yields and favorable weather conditions in Vietnam have helped reduce costs slightly. Export volume from Southeast Asia increased, improving availability.
- Q3 2025: $6,880/MT
Nodakenin production peaked in this quarter, leading to increased inventories and a softening in prices. However, increased demand in nutraceuticals prevented a major drop.
- Q4 2025 (projected): $7,000/MT
Demand is expected to rise again as global health supplement markets introduce seasonal immunity products featuring Nodakenin. Limited additional capacity expansion may keep prices buoyant.
Global Nodakenin Import-Export Business Overview
Nodakenin has grown from being a niche compound in traditional medicine to becoming an important active ingredient in mainstream pharmaceutical and nutraceutical markets globally. As of 2025, the global trade in Nodakenin is robust, with key importers being the United States, Germany, Japan, France, and India, while major exporters include South Korea, China, and Vietnam.
South Korea continues to dominate the production of high-purity Nodakenin, with over 45% of the global Nodakenin sales volume originating from its GMP-certified facilities. Korean exporters benefit from established quality protocols and long-standing relationships with Japanese and European buyers. China, on the other hand, has focused on bulk production with competitive pricing. In recent years, several Chinese producers have upgraded their facilities to meet EU compliance norms, allowing greater penetration into the European market.
Vietnam has emerged as a rising player, driven by government-backed agricultural reforms and investment in botanical extraction plants. Vietnamese exporters have seen their Nodakenin production rise by over 18% year-on-year, making the country a strong third in global export rankings. The export value from Vietnam is also increasing as the purity and processing methods improve to meet international standards.
On the importing side, the United States remains the largest consumer of Nodakenin, primarily for use in functional supplements, cognitive enhancers, and botanical-based drugs. The country imports over 2,500 MT annually. FDA guidelines around herbal compounds have encouraged manufacturers to shift toward regulated, quality-assured imports, which has improved the margins for exporters.
Germany and France together account for over 20% of global Nodakenin imports, mostly for integration into cosmetic and anti-aging formulations. Europe has seen a sharp increase in Nodakenin-based product launches in the last two years, with demand expected to continue growing through 2026.
Japan, although traditionally a producer, now imports a significant share due to the aging workforce in agriculture and higher domestic production costs. This makes Japanese firms more reliant on Korean and Vietnamese sources.
India has shown the fastest growth in demand for Nodakenin, spurred by the booming Ayurveda and herbal supplement sectors. Local producers are limited in number, so imports dominate the Indian market. Regulatory streamlining by the Ministry of AYUSH has made it easier for Indian importers to contract with South Korean suppliers.
The logistics of global Nodakenin trade are becoming more streamlined. Major port expansions in Busan (South Korea), Ho Chi Minh City (Vietnam), and Shanghai (China) have reduced export lead times. However, container shortages and fuel cost fluctuations continue to influence trade margins.
Another development in the global Nodakenin business is the rise of long-term offtake agreements. Buyers in the US and EU are increasingly entering into 2–3 year contracts to secure price and volume stability. These agreements have led to more predictable production planning for suppliers and reduced price volatility.
Sustainability is also playing a growing role. Ethical sourcing and organic certification of Angelica gigas are being prioritized by European and North American buyers. This has led to a rise in certified-organic Nodakenin exports, with premium pricing attached.
Challenges in the import-export business include inconsistent regulatory frameworks between countries, phytosanitary restrictions, and pricing pressures due to synthetic alternative development. Still, the overall outlook for global Nodakenin trade in 2025 remains strong, with a projected 9% increase in overall trade volume compared to 2024.
The ongoing developments in extraction methods, the emergence of new use cases in medicine, and more advanced logistics networks are expected to shape the next phase of growth for the Nodakenin industry.
For more detailed information and data-driven insights on this compound’s market trajectory, you can https://datavagyanik.com/reports/nodakenin-market/
Nodakenin Production Trends by Geography (2025)
Nodakenin production is geographically concentrated in East and Southeast Asia, where the primary source plant, Angelica gigas, is native and widely cultivated. Over the past decade, advancements in cultivation techniques, extraction technology, and export infrastructure have contributed to the steady rise in Nodakenin production globally. As of 2025, the key countries involved in large-scale production are South Korea, China, Vietnam, and to a lesser extent, Japan and India. Each region brings unique strengths and challenges to the global Nodakenin supply chain.
South Korea remains the dominant force in Nodakenin production. It has been a long-standing hub due to the historical and medicinal use of Angelica gigas in Korean herbal medicine. South Korea’s industry is supported by robust research institutions, skilled labor, and well-regulated cultivation practices. The country produces pharmaceutical-grade Nodakenin in large volumes using high-yield extraction facilities, especially in North Gyeongsang and Gangwon provinces. In 2025, South Korea is expected to account for nearly 38% of the global Nodakenin production. Producers here emphasize purity and bioactivity, making their output particularly attractive to pharmaceutical and nutraceutical industries in Japan, the United States, and Europe.
China has significantly increased its production capacity in recent years. Large plantations in the Yunnan and Sichuan provinces supply the raw material, and the country is rapidly modernizing its extraction facilities. While traditionally known for lower-cost production, Chinese producers are beginning to close the quality gap with South Korea. In 2025, China is projected to contribute about 32% of global Nodakenin production. Chinese firms benefit from economies of scale and a broad domestic market, which enables large-scale continuous processing. Many export-focused manufacturers have adopted EU-compliant production standards, making their products more competitive internationally.
Vietnam is an emerging player in the Nodakenin market. The country has invested heavily in agricultural research and processing infrastructure under government-backed herbal industry promotion programs. Central Highlands and Northern Vietnam have seen rapid expansion of Angelica gigas cultivation. Vietnamese producers are leveraging lower labor costs and favorable climate conditions to grow their market share. Although current production volumes are still smaller compared to South Korea and China, Vietnam is showing double-digit annual growth. By the end of 2025, it is expected to contribute around 15% of global Nodakenin supply. A growing number of companies are forming strategic partnerships with Korean and Japanese firms to improve their technical capabilities.
Japan, though an early adopter in the pharmaceutical applications of Nodakenin, has reduced its domestic production due to aging agricultural labor and land constraints. Instead, Japanese companies now import most of their raw material while focusing on high-end formulation, clinical trials, and product innovation. Domestic production now accounts for only about 5% of global supply, but Japanese firms play a crucial role in standardization, testing, and advanced formulation of Nodakenin products.
India is a new entrant in Nodakenin production, with cultivation trials taking place in the Himalayan and Northeastern regions where climatic conditions are favorable for Angelica gigas. The production scale remains limited, but several herbal manufacturers are looking to develop in-house sourcing capabilities. Given the growing demand from the local Ayurveda and herbal supplements market, domestic production in India is expected to gain traction over the next few years.
Other regions, such as Eastern Europe and North America, are exploring controlled cultivation of Angelica gigas under greenhouse conditions, though commercial-scale production is not yet viable. These efforts are primarily driven by research institutions and pharmaceutical firms aiming to secure local supply chains.
In summary, the geographic spread of Nodakenin production in 2025 reflects a blend of mature producers like South Korea and China, rising competitors such as Vietnam, and aspirants including India and Japan with strategic shifts in focus. The global landscape is expected to continue evolving as climate change, land use policies, and biotechnological innovations influence where and how Nodakenin is produced.
Nodakenin Market Segmentation
The Nodakenin market is segmented across various axes including application, end-use industry, purity level, distribution channel, and geography. The following are the major market segments:
- Application
- Pharmaceuticals
- Nutraceuticals
- Cosmetics and Personal Care
- Research and Development
- End-Use Industry
- Healthcare
- Wellness and Supplements
- Herbal Formulation Manufacturers
- Contract Manufacturing Organizations (CMOs)
- Purity Level
- 98% and above (pharmaceutical grade)
- 95%–98% (commercial grade)
- Below 95% (technical or research grade)
- Distribution Channel
- Direct Sales
- Online Retail
- Distributors and Wholesalers
- Specialty Stores
- Geography
- Asia-Pacific
- North America
- Europe
- Latin America
- Middle East and Africa
Among these segments, pharmaceuticals and nutraceuticals remain the largest consumers of Nodakenin in 2025. The compound’s strong antioxidant, anti-inflammatory, and neuroprotective properties have made it a key ingredient in various treatments, especially those related to cognitive health, neurodegenerative disorders, and chronic inflammation. Clinical research supporting its efficacy has prompted pharmaceutical firms to invest in long-term sourcing contracts and product development pipelines.
The nutraceuticals segment is showing the fastest growth. Nodakenin is increasingly included in dietary supplements, brain health enhancers, and wellness products, often marketed as a natural remedy for stress, anxiety, and mental clarity. This segment is especially strong in North America and Europe, where clean-label and plant-based supplement demand is rising. The growth of e-commerce platforms has also helped distribute Nodakenin supplements directly to consumers.
In terms of end-use industry, the healthcare sector remains the dominant buyer, especially in the formulation of anti-aging and neuroprotective drugs. Herbal formulation manufacturers are also emerging as key customers, particularly in Asia, where traditional medicine systems integrate modern extraction techniques for better efficacy.
Based on purity, the pharmaceutical-grade Nodakenin segment is the most lucrative. Products with purity levels above 98% command premium prices and are preferred by regulatory-compliant firms in developed markets. These are primarily produced in South Korea and Japan. Commercial-grade products with slightly lower purity are more common in the cosmetics and wellness sectors. Technical-grade Nodakenin finds its use in academic research and pre-clinical studies.
The distribution landscape has shifted considerably. While direct B2B sales remain the dominant channel for large-volume pharmaceutical buyers, the rise of online retail and specialty platforms has democratized access for smaller manufacturers and individual consumers. Online distribution is growing at an accelerated pace in North America and Europe, supported by digital health trends and subscription-based models for supplements.
Geographically, Asia-Pacific continues to lead in both production and consumption, followed by North America. Europe’s demand is increasing steadily due to regulatory approval of herbal-based ingredients in health and cosmetic products. Latin America and the Middle East are showing signs of uptake, though market penetration remains limited due to infrastructure and regulatory gaps.
Overall, the Nodakenin market in 2025 is defined by its diversification across applications, growing end-user base, and geographic expansion. Market segmentation continues to evolve with ongoing clinical research, shifting consumer behavior, and technological advancements in herbal processing.